Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CK-2017357 in ALS
NCT01089010Phase 2Completed
- Sponsor
- Cytokinetics
- Start
- Mar 2010
- Primary completion
- Nov 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tirasemtiv in amyotrophic lateral sclerosis (ALS), sponsored by Cytokinetics. Started Mar 2010; status: completed.
02
Drugs
tirasemtiv
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT01089010.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01089010.